JP Morgan Chase
INDV icon

JP Morgan Chase’s Indivior Pharmaceuticals INDV Stock Holding History

JP Morgan Chase’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Sell
269,603
-270,260
-50% -$9.8M ﹤0.01% 2691
2026
Q1 		$15.5M Buy
539,863
+328,655
+156% +$10.9M ﹤0.01% 2296
2025
Q4 		$7.58M Buy
211,208
+3,620
+2% +$111K ﹤0.01% 2949
2025
Q3 		$5M Sell
207,588
-183,798
-47% -$3.85M ﹤0.01% 3363
2025
Q2 		$5.77M Buy
391,386
+340,498
+669% +$3.97M ﹤0.01% 3017
2025
Q1 		$485K Sell
50,888
-13,902
-21% -$146K ﹤0.01% 4798
2024
Q4 		$805K Sell
64,790
-376,955
-85% -$3.88M ﹤0.01% 4773
2024
Q3 		$4.31M Sell
441,745
-953,120
-68% -$11.2M ﹤0.01% 3322
2024
Q2 		$22.5M Sell
1,394,865
-273,991
-16% -$4.95M ﹤0.01% 1780
2024
Q1 		$35.7M Buy
1,668,856
+738,654
+79% +$13.9M ﹤0.01% 1484
2023
Q4 		$14.2M Buy
930,202
+127,978
+16% +$2.27M ﹤0.01% 2137
2023
Q3 		$18.5M Sell
802,224
-168,399
-17% -$3.84M ﹤0.01% 1738
2023
Q2 		$23.1M Buy
+970,623
New +$22.2M ﹤0.01% 1594

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's INDV Position: Q2 2026 in Review

JP Morgan Chase reduced its Indivior Pharmaceuticals (INDV) stake by 50% in Q2 2026, selling an estimated $9.8M and leaving 269,603 shares worth $11.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2691.

JP Morgan Chase first reported a position in INDV in Q2 2023 and has held it in 13 quarters since. The position peaked at $35.7M in Q1 2024. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • JP Morgan Chase held 269,603 shares of Indivior Pharmaceuticals worth $11.3M as of Q2 2026.
  • JP Morgan Chase sold 270,260 Indivior Pharmaceuticals shares in Q2 2026, an estimated $9.8M.
  • Indivior Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2691 holding.
  • JP Morgan Chase first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • JP Morgan Chase's Indivior Pharmaceuticals position peaked at $35.7M in Q1 2024.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.